{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-018617","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.118227+00:00","generated_at":"2026-06-21T04:50:52.283067+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Passage Bio reports positive interim Phase 1/2 data for PBGM01 in GM1 gangliosidosis","bullets":["No treatment-related SAEs; all AEs mild-moderate; no DRG toxicity or ICM administration complications.","Dose-dependent CSF β-Gal activity increases (up to 5.2-fold) and GM1 ganglioside decreases (up to 75%) in high-dose cohort.","Patients with milder baseline developmental delay showed meaningful improvement on Vineland and Bayley scales.","Cohort 4 fully dosed; data expected by mid-2023; conference call held December 14, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-018617","json":"https://secwatch.observer/filing/0001558370-22-018617.json","markdown":"https://secwatch.observer/filing/0001558370-22-018617.md","text":"https://secwatch.observer/filing/0001558370-22-018617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022018617/0001558370-22-018617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022018617/pasg-20221214x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:50:52.283067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}